Beyond Major Pathologic Response in Lung Cancer: Biomarkers Predict Outcomes
Neoadjuvant chemoimmunotherapy improves outcomes in resectable non-small cell lung cancer, yet pathologic response incompletely predicts durability of benefit. Spatial profiling using resected tumors and lymph nodes revealed distinct immune subtypes and identified a gene signature associated with improved outcomes, providing a framework for biomarker-guided treatment selection and prospective validation.
Authors
- Johannes R. Kratz (ORCID: https://orcid.org/0000-0003-0696-4073)
- Natalie Ward (ORCID: https://orcid.org/0000-0001-8365-332X)
- Victoria E. Wang
Institutions
- University of California, San Francisco (US)
- University of San Francisco (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-09-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-26-2536
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00